Prevention of peritoneal carcinomatosis from human gastric cancer cells by adjuvant-type intraperitoneal immunotherapy in a SCID mouse model

European Surgical Research

Volumn 35, Issue 6, 2003, Pages 470-476

  Piso, P ^a   Aselmann, H ^a   Von Wasielewski, R ^a   Dahlke, M H ^b   Klempnauer, J ^a   Schlitt, H J ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Immunotherapy; Peritoneal carcinomatosis; SCID mouse

Indexed keywords

EDRECOLOMAB; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURGERY; CARCINOMATOSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; IMMUNOTHERAPY; LYMPHOKINE ACTIVATED KILLER CELL; METASTASIS; NONHUMAN; OBSERVATION; PERITONEUM CANCER; PERITONEUM TUMOR; PRIORITY JOURNAL; SCID MOUSE; STATISTICAL SIGNIFICANCE; STOMACH CARCINOMA; TUMOR CELL; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRAPERITONEAL; KILLER CELLS, LYMPHOKINE-ACTIVATED; MICE; MICE, SCID; MIDDLE AGED; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0242383212     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073385     Document Type: Article

References (23)

1. Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Fujimura T, Miwa K: Intraoperative lavage for cytological examination in 129 patients with gastric carcinoma. Am J Surg 1999;178:256-262.
2. Bennett J, Kooby DA, Delman K, McAuliffe P, Haltermann AW, Fong Y: Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J Mol Med 2000;78:166-174.
3. Bonenkamp JJ, Sogun I, Hermans J, van der Velde C: Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Br J Surg 1996;83:672-674.
4. Canevari S, Stoter G, Arietini F, Bolis G, Colnaghi MI, Warnaar SO, Bolhuis RLH: Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T-lymphocytes retargeted by a bispecific monoclonal antibody. J Nat Cancer Inst 1995;87:1463-1469.
5. Eggermont AM, Sugarbaker PH, Marquet RL, Jeeke J: Synergistic antitumor activity of cyclophosphamide and ABPP in the treatment of established and advanced tumors in murine tumor model. Cancer Immunol Immunother 1987;25:16-24.
6. Eggermont AMM, Steller EP, Ottow RT, Matthews W, Sugarbaker PH: Augmentation of interleukin-2 immunotherapeutic effects by lymphokine activated killer cells: Reduction of tumor and survival benefits in the murine models. Cell Immunol 1987:29:58-71.
7. Frasci G, Tortoriello A, Facchini G: Carboplatin and alpha-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer: A pilot study. Eur J Cancer 1994;30:946-950.
8. Freedman RS, Lenzi R, Kudelka AP, Lawrence DD, Rosenblum M, Platsoucas CD: Intraperitoneal immunotherapy of peritoneal carcinomatosis. Cytokines Cell Mol Ther 1998;4:12-140.
9. Hayes N, Wayman J, Wadhera V, Scott DJ, Raimes SA, Griffin SM: Peritoneal cytology in the surgical evaluation of gastric carcinoma. Br J Cancer 1999;79:520-524.
10. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T: Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999;85:529-534.
11. Illiger HJ: Der monoklonale Antikörper 17-1A (Panorex) - Ein neuer Ansatz zur adjuvanten Therapie des Kolonkarzinoms. Internist 1997;38:1001-1007.
12. Ishii H, Gouchi A, Orita K: The enhancement of cell surface ICAM-I and HLA class I antigens in human gastric cancer cell lines by IFN-gamma. Acta Med Okayama 1994;48:73-79.
13. Kärre K: NK Cells, MHC class I molecules and the missing self. Scand J Immunol 2002;5:221-228.
14. Lamers CHJ, Bolhuis LH, Warnaar SO, Stoter G, Gratama JW: Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bispecific monoclonal antibody. Int J Cancer 1997;73:211-219.
15. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L: What is a natural killer cell? Nat Immunol 2002;3:6-8.
16. Nekarda H, Gess G, Stark M, Mueller JD, Fink U, Schenck U, Siewert JR: Immunocytochemically detected free peritoneal tumor cells are strong prognostic factor in gastric carcinoma. Br J Cancer 1999;79:611-619.
17. Okamoto K, Yamaguchi T, Otsuji E, Yamaoka N, Yata Y, Tsuruta H, Kitamura K: Targeted chemotherapy in mice with peritoneally disseminated gastric cancer using monoclonal antibody-drug conjugate. Cancer Lett 1998;122:231-236.
18. Ottow RT, Steller EP, Sugarbaker PH, Wesley RA, Rosenberg SA: Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine activated killer cells: Reduction of tumor and survival benefits in the murine models. Cell Immunol 1987;29:58-71.
19. Schumann J, Pantel K: Panorex/mAk 17-1A: Literaturübersicht Glaxo-Wellcome, 1998.
20. Sugarbaker PH, Yonemura Y: Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: Best palliation with a ray of hope for cure. Oncolgy 2000;58:96-107.
21. Wunderlich JR, Mezzanzanica D, Garrido MA, Neblock DS, Daddona PE, Andrew SM, Zurawski VR, Canevari S, Segal DM: Bispecific antibodies and retargeted cellular cytotoxicity: Novel approaches to cancer therapy. Int J Clin Lab Res 1992;22:17-20.
22. Yamamoto T, Arakawa F, Nakamura K, Senba T, Tomita Y, Ikeda S, Kuroki M: Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model. Cancer Immunol Immunother 1999;48:165-171.
23. Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH: Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: Results of a prospective randomised trial. World J Surg 2001;25:985-990.